Guangzhou Boji Medical and Biotechnological Co Ltd

Canature Health's wholly-owned subsidiary Shanghai Yuantian Biotechnology has officially signed a technical service entrustment contract with Boji Medical, marking the formal entry of YT001 Injection, a Class 1 biologic new drug independently developed by Yuantian Biotechnology for knee osteoarthritis, into the clinical trial stage. YT001 Injection received implied clinical trial approval from the Center for Drug Evaluation of the National Medical Products Administration in October 2024, intended for the treatment of knee osteoarthritis, which has a symptomatic prevalence rate of 8.1 percent in China. Traditional treatment options have shown limited efficacy for some patients, and no cell-based therapy has been approved domestically for knee osteoarthritis. Under the agreement, Boji Medical will serve as the full-process contract research organization, responsible for organizing and implementing the Phase I and Phase II clinical studies of YT001 Injection as well as full-process quality management. Founded in 2016, Yuantian Biotechnology was originally a project company incubated by Yuanneng Cell Technology Group, which was wholly established by Canature Health, and was merged into the listed company system at the end of last year. It is the core subsidiary of the company's cell business segment.

Yipinhong's wholly owned subsidiary, Yipinhong Pharmaceutical, plans to sign a technical service contract with Boji Medical, commissioning it to conduct a clinical study for the innovative drug APH04935 tablets. The total contract value is 6.5 million yuan, tax inclusive. This transaction constitutes a related-party transaction because Yipinhong's independent director Zhang Kejian also serves as a non-independent director of Boji Medical. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.